改良的半胱天冬酶-3检测表明，半胱天冬酶-3活性与非人灵长类动物对鼠疫耶尔森菌感染的免疫力相关。
Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection.
作者信息
Welkos Susan, Norris Sarah, Adamovicz Jeffrey
机构信息
Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA.
出版信息
Clin Vaccine Immunol. 2008 Jul;15(7):1134-7. doi: 10.1128/CVI.00091-08. Epub 2008 May 14.
Abstract
Defined candidate human vaccines for treating infection by Yersinia pestis, the agent of plague, have been developed. To facilitate evaluation of the vaccines' efficacy, the in vitro caspase-3 assay for cytotoxicity-neutralizing activity was modified and reevaluated. Immune serum-mediated caspase-3 neutralizing activity correlated with protection against infection in a nonhuman primate vaccine model of plague immunity.
摘要
已经开发出了确定的用于治疗由鼠疫杆菌（鼠疫的病原体）引起的感染的候选人类疫苗。为便于评估疫苗的效力，对用于检测细胞毒性中和活性的体外半胱天冬酶-3检测方法进行了改进和重新评估。在鼠疫免疫的非人灵长类动物疫苗模型中，免疫血清介导的半胱天冬酶-3中和活性与抗感染保护作用相关。
相似文献
1
Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection.
Clin Vaccine Immunol. 2008 Jul;15(7):1134-7. doi: 10.1128/CVI.00091-08. Epub 2008 May 14.
2
Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Vaccine. 2008 Mar 20;26(13):1616-25. doi: 10.1016/j.vaccine.2008.01.033. Epub 2008 Feb 6.
3
Development of in vitro correlate assays of immunity to infection with Yersinia pestis.
Clin Vaccine Immunol. 2007 May;14(5):605-16. doi: 10.1128/CVI.00398-06. Epub 2007 Mar 21.
4
Immune defense against pneumonic plague.
Immunol Rev. 2008 Oct;225:256-71. doi: 10.1111/j.1600-065X.2008.00674.x.
5
Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Vaccine. 2019 Sep 10;37(38):5708-5716. doi: 10.1016/j.vaccine.2019.07.103. Epub 2019 Aug 12.
6
Cell-mediated protection against pulmonary Yersinia pestis infection.
Infect Immun. 2005 Nov;73(11):7304-10. doi: 10.1128/IAI.73.11.7304-7310.2005.
7
Complete Protection Against in BALB/c Mouse Model Elicited by Immunization With Inhalable Formulations of rF1-V10 Fusion Protein Aerosolized Intratracheal Inoculation.
Front Immunol. 2022 Jan 26;13:793382. doi: 10.3389/fimmu.2022.793382. eCollection 2022.
8
Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
mBio. 2021 Dec 21;12(6):e0322321. doi: 10.1128/mBio.03223-21. Epub 2021 Dec 7.
9
A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
Clin Vaccine Immunol. 2016 Jul 5;23(7):586-600. doi: 10.1128/CVI.00150-16. Print 2016 Jul.
10
A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection.
Microb Pathog. 2010 May;48(5):191-5. doi: 10.1016/j.micpath.2010.01.005. Epub 2010 Jan 22.
引用本文的文献
1
A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
Clin Vaccine Immunol. 2016 Jul 5;23(7):586-600. doi: 10.1128/CVI.00150-16. Print 2016 Jul.
2
Plague vaccines: current developments and future perspectives.
Emerg Microbes Infect. 2012 Nov;1(11):e36. doi: 10.1038/emi.2012.34. Epub 2012 Nov 7.
3
Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.
Adv Prev Med. 2012;2012:731604. doi: 10.1155/2012/731604. Epub 2011 Oct 17.
4
The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.
Adv Prev Med. 2012;2012:365980. doi: 10.1155/2012/365980. Epub 2011 Sep 29.
5
TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
Vaccine. 2010 Dec 16;29(2):357-62. doi: 10.1016/j.vaccine.2010.08.099. Epub 2010 Sep 15.
6
Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.
Clin Vaccine Immunol. 2009 Dec;16(12):1720-7. doi: 10.1128/CVI.00333-09. Epub 2009 Oct 14.
7
Pneumonic plague pathogenesis and immunity in Brown Norway rats.
Am J Pathol. 2009 Mar;174(3):910-21. doi: 10.2353/ajpath.2009.071168. Epub 2009 Jan 22.
8
Antibodies and cytokines independently protect against pneumonic plague.
Vaccine. 2008 Dec 9;26(52):6901-7. doi: 10.1016/j.vaccine.2008.09.063. Epub 2008 Oct 14.
9
Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.
Infect Immun. 2008 Dec;76(12):5588-97. doi: 10.1128/IAI.00699-08. Epub 2008 Sep 15.
本文引用的文献
1
Development of in vitro correlate assays of immunity to infection with Yersinia pestis.
Clin Vaccine Immunol. 2007 May;14(5):605-16. doi: 10.1128/CVI.00398-06. Epub 2007 Mar 21.
2
Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis.
Microb Pathog. 2002 May;32(5):227-37. doi: 10.1006/mpat.2002.0498.
3
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.
JAMA. 2000 May 3;283(17):2281-90. doi: 10.1001/jama.283.17.2281.
4
The looming threat of bioterrorism.
Science. 1999 Feb 26;283(5406):1279-82. doi: 10.1126/science.283.5406.1279.
5
Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.
Vaccine. 1998 Jul;16(11-12):1131-7. doi: 10.1016/s0264-410x(98)80110-2.
6
A new improved sub-unit vaccine for plague: the basis of protection.
FEMS Immunol Med Microbiol. 1995 Dec;12(3-4):223-30. doi: 10.1111/j.1574-695X.1995.tb00196.x.
Zotero 插件